Who is sponsoring NCT01017159?

NCT01017159 is sponsored by University of Aarhus.

What drugs are being tested in NCT01017159?

Interventions in NCT01017159: Subcutaneous immunoglobulin.

What condition does NCT01017159 study?

NCT01017159 studies Polyradiculoneuropathy, Chronic Inflammatory Demyelinating.

Is NCT01017159 still recruiting?

NCT01017159 is currently completed. Last updated 9 November 2011.

Last reviewed 2011-11-09 · How we verify

NCT01017159

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomised, Double-blinded, Placebo-controlled Trial of Subcutaneous Immunoglobulin Treatment in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Completed Phase 2 Last updated 9 November 2011

What this trial tests

Phase 2 trial testing Subcutaneous immunoglobulin in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in 30 participants. Completed in 1 November 2011.

Timeline

1 April 2010

Primary endpoint
1 November 2011

1 November 2011

Quick facts

Lead sponsor	University of Aarhus
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	30
Start date	1 April 2010
Primary completion	1 November 2011
Estimated completion	1 November 2011
Sites	1 location across Denmark

Drugs / interventions tested

Subcutaneous immunoglobulin — full drug profile →

Conditions studied

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating — all drugs for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating →

Sponsor

University of Aarhus

Who can join

Adults 18 to 80, any sex, with Polyradiculoneuropathy, Chronic Inflammatory Demyelinating. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Strength assessed by isokinetic strength measurements, in the active treatment group compared with the placebo group.
Time frame: The study period is 98 days. Isokinetic strength will be measured on day 14, 28, 84 and 98 of the study period. If there is a drop-out before day 84, the strength measurement will take place on this day, and the last two measurements will be left out.

Sponsor's own description

The purpose of this study is to determine whether subcutaneous immunoglobulin given in small doses, is effective in maintaining the force, in patients with chronic inflammatory demyelinating polyradiculoneuropathy compared with placebo (saline infusions), and intravenous immunoglobulin.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Intravenous immunoglobulin as clinical immune-modulating therapy.
Gilardin L, Bayry J, Kaveri SV. · · 2015 · cited 63× · PMID 25667260 · DOI 10.1503/cmaj.130375

Verify or expand the search:

Other recruiting trials for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Currently open trials in the same condition.

NCT05327114 — Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Phase 2, PHASE3 · recruiting

Other University of Aarhus trials

Trials by the same sponsor.

NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01017159 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
Last refreshed: 9 November 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01017159.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing